Avalo TherapeuticsAVTX
13F holders, Q1 2024 (March 31)18holders
$21.69avg. 13F price*
At the end of Q1 2024, 18 institutions reported holding Avalo Therapeutics Inc. (AVTX) in their 13F filings. The largest holders were Ikarian Capital, LLC ($1.0M), Sio Capital Management, LLC ($221K) and Affinity Asset Advisors, LLC ($218K).
- Company
- Avalo Therapeutics Inc.
- CUSIP
- 05338F306
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 8 | $1.6M |
| Exits | 2 | $4K |
Ownership 18 holders
| Ikarian Capital, LLC | 0.28% | New | 46,648 | $1.0M |
| Sio Capital Management, LLC | 0.08% | New | 10,151 | $221K |
| Affinity Asset Advisors, LLC | 0.04% | New | 10,000 | $218K |
| UBS Group AG | 0.00% | Add +385550.0% | 7,713 | $168K |
| ADAR1 Capital Management, LLC | 0.04% | New | 6,000 | $131K |
| Natixis | 0.00% | Reduce -45.4% | 2,512 | $55K |
| BlackRock Inc. | 0.00% | Reduce -86.6% | 2,124 | $46K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -7.1% | 1,640 | $36K |
| Royal Bank of Canada | 0.00% | Add +133.3% | 322 | $7K |
| Banque Cantonale Vaudoise | 0.00% | New | 338 | $2K |
| Morgan Stanley | 0.00% | Reduce -11.4% | 39 | $848 |
| Wells Fargo & Company | 0.00% | No change | 8 | $175 |
| BNP Paribas Financial Markets | 0.00% | New | 4 | $87 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $44 |
| Group One Trading LLC | 0.00% | No change | 2 | $44 |
| Osaic Holdings, Inc. | 0.00% | Add +100.0% | 2 | $43 |
| Towne Trust Company, N.A | 0.00% | New | 1 | $22 |
| Parallel Advisors, LLC | 0.00% | New | 1 | $22 |
"% of holder's portfolio" is AVTX's weight in each manager's 13F, not the share of Avalo Therapeutics Inc. the manager owns.